BioSpace News Archive

NanoCellect Biomedical Inc. announced the close of $35M of financing to further accelerate commercial growth plans and new product development goals.

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00 per share.

Evofem Biosciences, Inc., today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021 .

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with BEC GmbH (BEC) to incorporate a customized, robotic patient positioning system as part of its Alphabeam™ Neutron System for the high-precision radiation treatment of tumors.

DESTINY-Gastric06 Phase 2 Trial of ENHERTU ® Initiated in China in Patients with HER2 Positive Advanced Gastric Cancer

Cardialen , Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for the development of an implantable, low-energy therapy for the cardioversion of atrial fibrillation (AF).

Aileron Therapeutics today presented new clinical data at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 supporting ALRN-6924’s best-in-class potential as a chemoprotective agent.

- Validated clinical pharmacology and positive psoriasis proof-of-concept clinical study with synthetic hypericin sets stage for pipeline expansion

Sept. 16, 2021 12:35 UTC reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD)

Genesis Drug Discovery & Development, the contract research organization arm of Genesis Biotechnology Group®, has announced the appointment of Anthony Rohr, current Chief Executive Officer of PharmOptima, as its new Chief Operating Officer.